Hakkımızda
  • Medicheck was established in Silivri to produce radiopharmaceutical products.

  • Strategic cooperation agreement signed with GE Healthcare.

  • Plant construction is completed in 8 months.

  • FDG technology transfer agreement was signed with GE Healthcare.

  • Comercial production started with SteriFDG (18F-FDG)

  • Distributorship agreement signed with Medi-Radiopharma.

  • Medicheck was qualified as service provider in radiopharmacy for GE Healthcare.

  • Brain-Spect (HMPAO) and Cardio-Spect (MIBI) kits were introduced to the market.

  • Senti-Scint (Nanocolloid) and Macro Albumon (MAA) kits were introduced to the market.

  • Distributorship agreement signed with GE Healthcare.

  • Product portfolio was expanded with SteriNaF (18F-NaF).

  • Flutemetamol technology transfer agreement was signed with GE Healthcare.

  • DaTSCAN® (123I-Ioflupane) marketing authorization was obtained.

  • Vizamyl® (18F-Flutemetamol) marketing authorization was obtained.

  • Renoscint (MAG3) Marketing Authorization application was submitted.

 
#
Tamam